A phase I/II study of PI3Kinase inhibition with copanlisib combined with the anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in MSS colorectal cancer.

TPS4114Background: Certain somatic mutations are thought to promote immune evasion and resistance to immunotherapy. PIK3CA was identified in an in vivo genomic screen for mechanisms of resistance t...